Trial Profile
A 24-Week, Multi-Centre Trial, Comprising A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase Followed By A 12-Week Open-Label Phase, To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms SOFIA
- Sponsors Pfizer
- 23 Jan 2012 Actual patient number (31) added as reported by ClinicalTrials.gov (Extension trial: NCT01054222).
- 23 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov (Extension trial: NCT01054222).
- 23 Jan 2012 Status of the extension trial is completed (Extension trial: NCT01054222).